

References

1. US Food and Drug Administration. FDA approves ruxolitinib for acute graft-versus-host disease. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-acute-graft-versus-host-disease>. Accessed March 2, 2019.
2. Ali H, Snyder D, Stiller T, et al. Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning, ASH 2019. Abstract 669.
3. Cervantes F, Gisslinger H, Radinoff A, et al. Safety and efficacy of ruxolitinib (RUX) in patients with myelofibrosis (MF) and anemia (Hb <10 g/dL): Results at week (wk) 24 of the REALISE trial. EHA 2019. Abstract PS1465.
4. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med*. 2012;366:787-798.
5. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med*. 2012;366:799-780.
6. Pardanani A, Harrison CN, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. *JAMA Oncol*. 2015;1:643-651.
7. Harrison CN, Schapp N, Vannuchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Hematol*. 2017;4:e317-e324.
8. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. ASCO 2019. Abstract 7057.
9. Harrison CN, Schaap N, Vannucchi, et al. Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. *Blood*. 2019;134(Supplement_1):4165. https://ashpublications.org/blood/article/134/Supplement_1/4165/425748/Fedratinib-Induces-Spleen-Responses-in-Patients?searchresult=1
10. Harrison CN, Schaap N, Vannucchi, et al. Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib. *Blood*. 2019;134 (Supplement_1): 668. https://ashpublications.org/blood/article/134/Supplement_1/668/426503/Fedratinib-Induces-Spleen-Responses-and-Reduces?searchresult=1
11. Harrison CN, Schaap N, Vannuchi AM, et al. Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in

Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. ASH 2019. Abstract 2207.

12. Mesa RA, Schaap N, Vannuchi AM, et al. Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. ASH 2019. Abstract 704.
13. Mesa RA, Talpaz M, Kiladjian J-J, et al. Pacritinib demonstrates efficacy versus best available therapy in myelofibrosis patients with severe thrombocytopenia in two phase 3 studies. ASH 2019. Abstract 1495.
14. Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. *Lancet Haematol*. 2017;4:e225-e236.
15. Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis. Randomized clinical trial. *JAMA Oncol*. 2018;652-659.
16. Gerds AT, Savona MR, Scott BI, et al. Results of PAC203: a randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib. ASH 2019. Abstract 667.
17. Mesa RA, Catalano J, Cervantes F, et al. Dynamic and time-to-event analyses demonstrate marked reduction in transfusion requirements for Janus kinase inhibitor-naïve myelofibrosis patients treated with momelotinib compared head to head with ruxolitinib. ASH 2019. Abstract 1663.
18. Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. *J Clin Oncol*. 2017;35:3844-3850.